Amicus Therapeutics, Inc. and GlaxoSmithKline Commence Second Phase 3 Study of Amigal(TM) for Fabry Disease

CRANBURY, N.J. and LONDON, Sept. 12, 2011 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) and GlaxoSmithKline (GSK) today announced that the first patient has commenced dosing in a Phase 3 global registration study (Study 012) to compare the safety and efficacy of Amigal™ (migalastat HCl) and enzyme replacement therapy (ERT) for the treatment of Fabry disease. The randomized, open-label, 18-month study will provide longer-term clinical data comparing migalastat HCl to ERT in patients with Fabry disease, a rare inherited lysosomal storage disorder.